Successful entrepreneurs, experienced leading-edge scientific experts and researchers.

Click here to meet our management team


Recent announcements:


Proximagen notes positive vote from FDA advisory committee in respect of Arena’s 5-HT2c agonist lorcaserin


2011 Annual Report.


Proximagen Initiates Phase I Trial of Oral VAP-1 antagonist.


Proximagen and Altacor sign agreement for 5HT2c.


Proximagen signs strategic partnership agreement with Lundbeck.


Proximagen update by Edison Investment Research.


Proximagen acquires two CNS drug development programmes from GlaxoSmithKline.







Links to more press related content:


Regulatory announcements


Fact Sheet


Corporate Documents